807P First interim results of the radium-223 (Ra-223) REASSURE observational study: analysis of patient (Pt) characteristics and safety by use of abiraterone and/or enzalutamide (Abi/Enza).
Authors
Harshman, LLogue, John P
Sternberg, C
Sundar, S
Schrijvers, D
Schostak, M
Sylvester, J
George, S
Tucci, M
Mantz, C
Borrega, P
Ziem, P
Concepcion, R
Miller, K
Sartor, O
Kalinovsky, J
De Sanctis, Y
Tombal, B
Affiliation
Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, BostonIssue Date
2017-09
Metadata
Show full item recordCitation
807P First interim results of the radium-223 (Ra-223) REASSURE observational study: analysis of patient (Pt) characteristics and safety by use of abiraterone and/or enzalutamide (Abi/Enza). 2017, 28(suppl_5): Ann OncolJournal
Annals of OncologyDOI
10.1093/annonc/mdx370.024Additional Links
http://academic.oup.com/annonc/article/doi/10.1093/annonc/mdx370.024/4108893/807PFirst-interim-results-of-the-radium223-Ra223Type
Meetings and ProceedingsLanguage
enISSN
0923-75341569-8041
ae974a485f413a2113503eed53cd6c53
10.1093/annonc/mdx370.024